PHP
EIGR

Parkman Healthcare Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Parkman Healthcare Partners’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,758
Closed -$332K – 98
2022
Q2 		$332K Buy
1,758
+91
+5% +$18.3K 0.12% 74
2022
Q1 		$415K Buy
+1,667
New +$263K 0.12% 76

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Parkman Healthcare Partners's EIGR Position: Q3 2022 in Review

Parkman Healthcare Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2022, closing a stake of 1,758 shares — an estimated $332K sold.

Parkman Healthcare Partners first reported a position in EIGR in Q1 2022 and held it in 2 quarters. The position peaked at $415K in Q1 2022. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2022.

  • Parkman Healthcare Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 1,758 Eiger BioPharmaceuticals, Inc. shares in Q3 2022, an estimated $332K.
  • Parkman Healthcare Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2022 and held it in 2 quarters.
  • Parkman Healthcare Partners's Eiger BioPharmaceuticals, Inc. position peaked at $415K in Q1 2022.
  • 92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2022.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.